Radical Nephrectomy Articles

There remain discrepancies over the factors that influence oncologic outcomes after radical nephrectomy with thrombectomy (RNTE). To assess significant predictors of oncologic outcomes after RNTE from a systematic review and meta-analysis.

The tumor stage, size, grade, and necrosis (SSIGN) score was originally defined using patients treated with radical nephrectomy (RN) between 1970 and 1998 for clear cell renal cell carcinoma (ccRCC), excluding patients treated with partial nephrectomy (PN).

Five-year other cause mortality (OCM) after nephrectomy for non-metastatic renal cell carcinoma (RCC) should be marginal in properly selected surgical candidates. We examined 5-year OCM rates as a quality of care indicator for patient selection.

To test for an association between surgical delay and overall survival (OS) for patients with T2 renal masses. Many health care systems are balancing resources to manage the current COVID-19 pandemic resulting in surgical delay in patients with large renal masses.

SAN DIEGO, CA USA (UroToday.com) - The relationship between lipid metabolism and renal function is being increasingly recognized, although not well understood. Dr. Aditya Bagrodia and colleagues evaluated 905 patients undergoing radical nephrectomy (N=610) or partial nephrectomy (N=295) at multiple institutions.

BERKELEY, CA (UroToday.com) - In 1933, the surgeon Joseph Lazarus remarked that “there are few chapters in urology that are quite as discouraging to the surgeon as the chapter dealing with malignant tumors of the kidney.”

BERKELEY, CA (UroToday.com) - Even though the techniques reported were used in a very rare case of concomitant cancers in a native and a transplant kidney, the implications of this article can be viewed from several aspects for more practical use:

BERKELEY, CA (UroToday.com) - In this review article, we explored the contemporary role of surgical management of large renal tumors in both the clinically localized and metastatic settings.

BERKELEY, CA (UroToday.com) - The decision as to how to best treat a clinical stage I/II renal mass is often overly dependent on subjective variables such as physician experience and perception.

Surgical resection of renal cell carcinoma plays a large role in the overall management of the disease. The gold standard for surgical management historically has been open or laparoscopic radical nephrectomy, however, evidence of equivalent oncologic efficacy with improved clinical outcomes has driven the use of nephron-sparing surgeries, especially for smaller and localized renal tumors.

This study evaluated the relationship between histological markers of chronic kidney damage in patients undergoing radical nephrectomy for kidney tumours and preoperative kidney function, degree of albuminuria, and changes in glomerular volume.

With the addition of active surveillance and thermal ablation (TA) to the urologist's established repertoire of partial (PN) and radical nephrectomy (RN) as first-line management options for localized renal cell carcinoma (RCC), appropriate treatment decision-making has become increasingly nuanced.

To compare perioperative and oncologic outcomes for patients with clinical T1b renal cell carcinoma (RCC) following treatment with microwave ablation (MW), partial nephrectomy (PN) or radical nephrectomy (RN).

Owing to the limited ability of current imaging modalities, several clinical T1 renal cell carcinomas (cT1 RCCa) can be pathologically upstaged to T3a (pT3a) after surgery. There have been some controversies regarding the oncological safety of partial nephrectomy (PNx) compared with radical nephrectomy (RNx) in these patients.

Partial nephrectomy has been persuaded as a widely accepted surgical procedure for T1a (≤ 4 cm) renal tumors. However, when treating T1b (4-7 cm) renal cell carcinoma (RCC), the "optimal" method of surgery is still debatable.

The efficacy of partial nephrectomy (PN) for T1b renal cell carcinoma (RCC) is controversial. The oncological outcomes, the change in postoperative renal function and the perioperative complications are unclear.

To evaluate the association between severe skeletal muscle deficiency or sarcopenia and disease progression, cancer-specific (CSM), and all-cause mortality (ACM) among patients with localized renal cell carcinoma (RCC) treated with radical nephrectomy (RN).

To evaluate trends in the utilization of active surveillance (AS) in a nationally representative cancer database. AS has been increasingly recognized as a strategy for patients with small renal masses (SRM), but little is known about national usage patterns.

To develop and externally validate a model that quantifies the likelihood that a pathologically node-negative patient with clear cell renal cell carcinoma (cRCC) has, indeed, no lymph node metastasis (LNM).

There is no consensus regarding a protective effect on mortality due to cause other than cancer (OCM) for patients treated with elective nephron-sparing surgery (NSS) relative to their radical nephrectomy (RN) counterparts.

To investigate association of pre-treatment C-Reactive Protein (CRP) and non-cancer mortality (NCM) in a cohort of patients undergoing surgery for localized renal cell carcinoma (RCC).

Retrospective multicenter analysis of patients surgically treated for clinical stages 1-2 RCC from 2006-17, excluding all cases of cancer-specific mortality.

To analyze the suitability for metastasis evaluation of each pathologic item on the Fourth Edition of the General Rule for Clinical and Pathologic Studies on Renal Cell Carcinoma in Japan.

We retrospectively examined 457 cases of renal operation after 2011 using the current edition of the guidelines.

The Tumor-Node-Metastasis classification of renal cell carcinoma (RCC) for pT3a tumors includes sinus fat invasion (SFI), perinephric fat invasion (PFI), renal vein invasion (RVI), and/or pelvicaliceal system invasion (PSI).

To assess the impact of lymph node dissection (LND) extent on overall survival (OS) and cancer-specific survival (CSS) in patients with pN0M0 renal cell carcinoma (RCC) treated with radical nephrectomy (RN).

Despite better renal function following nephron-sparing surgery (NSS) relative to radical nephrectomy (RN), there is no consensus with respect to the long-term sequelae associated with surgery.

To investigate the effect of surgery and the temporal pattern of two different cardiovascular event (CVe) categories after NSS versus RN.

Data about the impact of surgical margin positivity on patient outcomes following radical nephrectomy (RN) for renal cell carcinoma (RCC) is limited. We evaluate the effect of positive surgical margins (PSMs) on relapse-free survival (RFS) and overall survival (OS.

This study aimed to evaluate the likelihood of progression to chronic kidney disease (CKD) in a cohort of geriatric Asian patients aged over 65 years who underwent either partial nephrectomy (PN) or radical nephrectomy (RN) for localised pT1 kidney tumours.

The objective of this study was to examine the effectiveness and safety of lower pole (LP) approach in retroperitoneal laparoscopic radical nephrectomy (LRN).

One hundred thirty-two renal cancer patients were scheduled for selective retroperitoneal LRN.

Cabozantinib (XL-184) is a small molecule inhibitor of the tyrosine kinases c-Met, AXL, and VEGFR2 that has been shown to reduce tumor growth, metastasis, and angiogenesis. After the promising results from the METEOR and CABOSUN trials, cabozantinib was approved for use in the first- and second-line setting in patients with advanced RCC.

Neoadjuvant Targeted Molecular Therapy in the setting of localized and locally advanced renal cell carcinoma has emerged as a strategy to render primary renal tumors amenable to planned surgical resection in settings where radical resection or nephron-sparing surgery was not thought to be safe or feasible.

To assess contemporary 30-day mortality rates after partial and radical nephrectomy in USA, and to develop a predictive model of 30-day mortality.

We relied on the National Cancer Institute Surveillance, Epidemiology and End Results database.

To compare the oncologic outcomes of partial nephrectomy (PN) and radical nephrectomy (RN) for cT1-2/N0 renal tumors and pathologically confirmed pT1-pT3a-pNx clear cell (cc)-renal cell carcinoma (RCC).

We aimed to study recurrence-free survival after partial versus radical nephrectomy for clinical stage T1 renal cell carcinoma among all comers and those upstaged to pathologic stage T3a.

A retrospective review of 1250 patients undergoing partial nephrectomy or radical nephrectomy for clinically localized T1 renal cell carcinoma between 2006 and 2014 was performed.

Partial nephrectomy (PN) is recommended for localized T1a (≤4 cm) renal masses and is preferred over radical nephrectomy (RN) for amenable T1b/T2 (>4 cm) tumors. The objective of the current study was to assess overall survival (OS) differences between PN and RN in patients with T1 and T2 renal cell carcinoma (RCC).

We conducted a meta-analysis to evaluate the efficiency and safety of partial nephrectomy (PN) compared with radical nephrectomy (RN) for large (≥7 cm) renal tumors. A comprehensive literature search with no restrictions on language or region was conducted from August up to October in 2018 in the electronic databases of PubMed, EMBASE, the Cochrane Library, and Scopus.

The majority of RCCs occur within the 7th decade of life, uncommonly arising in adults ≤46years. We reviewed the clinicopathologic features of early-onset renal cell carcinoma (RCC) and evaluated the role of immunohistochemistry (IHC) in potentially identifying diagnoses of newly recognized RCC subtypes that may have been previously misclassified.

Positive surgical margins (PSM) are recognized as an adverse prognostic sign and are often associated with higher rates of local and systemic disease recurrence. The data regarding the oncological outcome for PSM following radical nephrectomy (RN) is limited.

To predict of the risk of cancer-specific [CSM] or other-cause mortality [OCM] for T1 kidney cancer patients aiming at identifying those who would benefit from surgery over observation.

11,192 T1 kidney cancer patients treated with surgery or observation in the SEER-Medicare database were assessed.

To develop a clinically actionable predictive model to quantitate the risk of estimated glomerular filtration rate decline to ≤45 ml/min/1.73m2 following radical nephrectomy in order to better inform decisions between radical and partial nephrectomy.

Over the last decade, several nephrometry scores (NSs) have been introduced with the aim of facilitating preoperative decision making, planning, and counseling in the field of nephron-sparing surgery.

Renal cancer surgery (RCS) can adversely impact long-term function and survival. We evaluate predictors of chronic kidney disease (CKD) at 5-years and non-renal cancer mortality (NRCM) 10-years after RCS.

Birt-Hogg-Dubé syndrome (BHDS) is a rare autosomal dominant disease. It is caused by constitutional mutations in the FLCN gene. Since BHDS is a rare syndrome therefore it is unknown to many physicians.

Reduced port laparoscopic radical nephrectomy (RPLRN) is an equivalent approach to conventional laparoscopic radical nephrectomy (LRN). In LRN, one wound generally needs to be extended for specimen extraction; therefore, some ingenuity is needed to achieve a good cosmetic outcome.

Renal artery embolization is performed before radical nephrectomy (RN) for renal mass in order to induce preoperative infarction and to facilitate surgical intervention through decrease of intraoperative bleeding.

A clinicopathologic analysis of patients with renal cell carcinoma (RCC) and vena caval involvement diagnosed at our institution was performed. Multiple clinicopathologic parameters were examined. Fifty-three cases were identified.

There is a noticeable increase in the presentation of different types of urological malignancies at a younger age of presentation, in our institution. The objective of our study was to investigate cases presented with renal cell carcinoma, managed in the past 10 years for any possible epidemiological and cancer characteristics changes.

The rate of progression to metastatic disease in patients undergoing active surveillance for small renal tumors varies in the literature between 1% and 8%.

This study aims to examine the incidence of metastasis in small renal tumors of <4 cm in a Danish cohort.

A recent multi-center study showed how estimated glomerular filtration rate (eGFR) and cancer-specific mortality (CSM) are linearly and inversely related in organ-confined renal cell carcinoma (RCC) whenever the eGFR decreases below specific thresholds.

Sunitinib/sorafenib (SU/SO), dendritic cells (DCs), or DC-cytokine-induced killer (CIK) could significantly prolong progression-free survival (PFS), 3-year overall survival (OS), or 5-year OS for patients with metastatic renal cell carcinoma (mRCC).

Radical nephrectomy (RN) is the gold standard treatment for large and locally advanced renal tumors. Although robot-assisted radical nephrectomy (RRN) is being increasingly adopted, it remains unclear whether it offers benefits over standard laparoscopic radical nephrectomy (LRN) or open radical nephrectomy (ORN).